

1/26




FIG. 1




FIG. 2

3/26




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 4A




FIG. 4C




FIG. 4B




FIG. 4D

5/26




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D

6/26




FIG. 6B




FIG. 6A




FIG. 6C

8/26





FIG. 7

9/26




FIG. 7 CONT.

10/26




FIG. 8

11/26




FIG. 9A




FIG. 9B

12/26




FIG. 10

- Experimental Overview:**

  - CB.17 SCID mice
  - Tumor Dissemination Model (Xenograft)
  - Human MM1S (luciferase) MM cell line
  - Tumor burden quantified by intravital imaging (whole body bioluminescence)
  - 8 mice/group
  - Dosing by i.p. route of administration, 2X weekly
  - 8 week study
- Treatment Groups:**

  1. Vehicle Control
  2. mAb 2810, 4 mg/kg
  3. mAb 4320, variable dosing (4, 8, and 16 mg/kg)

Experimental Design




FIG. 11

14/26




FIG. 12




FIG. 13




FIG. 14

17/26




FIG. 15

18/26




FIG. 16

19/26




FIG. 17

20/26




FIG. 18A




FIG. 18B

Vehicle Control (Group 1, Mouse 7)




FIG. 19A

mAb 4320 (Group 2, Mouse 7)




FIG. 19B

Bortezomib (Group 3, Mouse 4)




FIG. 19C

mAb 4320 + Bortezomib (Group 7, Mouse 8)




FIG. 19D

25/26




FIG. 20




FIG. 21